UCB SELLS OTC DELSYM TO ADAMS RESPIRATORY THERAPEUTICS.UCB UCB - University of California at Berkeley S.A., Brussels, Belgium, has reached an agreement with Adams Respiratory Therapeutics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARxT) to sell Delsym (dextromethorphan polistirex), an over-the-counter (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). ) 12-hour liquid cough suppressant Cough suppressant Medicine that stops or prevents coughing. Mentioned in: Expectorants cough suppressant Medtalk A drug used to control a dry, annoying cough . In addition, the two companies have entered into a separate agreement for the licensing of the 12-hour liquid technology. The financial terms of the agreement consist of a one-time, upfront payment to UCB of 122 million U.S. dollars, royalties for a period of 5 years based on sales and a standard manufacturing supply agreement with a "cost-plus" structure. "This transaction is another step taken by UCB in its strategy to focus on research-driven innovation and novel therapeutic solutions for severe and chronic diseases treated by specialist physicians," declared Roch Doliveux, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of UCB. About Delsym Delsym is a cough medicine that doctors and pharmacists have recommended for years in the United States. It is the only OTC liquid cough suppressant than can deliver 12 hours of cough relief in a single dose. Delsym is made with a patented time-release formulation that allows the cough suppressant dextromethorphan to be available in the body over a 12-hour period. About Adams Respiratory Therapeutics, Inc. Adams is a U.S.-based specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over- the-counter and prescription pharmaceuticals for the treatment of respiratory disorders. For more information, visit http://www.adamsrt.com. About UCB UCB is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing 8,500 people in 40 countries, UCB achieved revenues of EUR EUR In currencies, this is the abbreviation for the Euro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 2.3 billion in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium. For more information, visit http://www.ucb-group.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion